Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer

Core Insights - Merck announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopted two positive opinions for KEYTRUDA® (pembrolizumab) [1] Group 1: Product Development - One opinion recommends approval of a new subcutaneous (SC) route of administration for KEYTRUDA® [1] - The second opinion supports a new pharmaceutical form (solution for injection) for KEYTRUDA® [1] - If approved, the new formulation would be marketed in Europe [1]